A Closer Look at 6 Analyst Recommendations For Allogene Therapeutics
Portfolio Pulse from Benzinga Insights
In the last three months, 6 analysts have published ratings on Allogene Therapeutics (NASDAQ:ALLO), with a mix of bullish and somewhat bullish sentiments. The average 12-month price target has decreased by 27.89% to $11.43. Analysts have adjusted their ratings and price targets in response to changing market dynamics and company performance.
August 08, 2024 | 2:01 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Allogene Therapeutics (NASDAQ:ALLO) has received mixed ratings from 6 analysts over the past three months, with a notable decrease in the average 12-month price target by 27.89% to $11.43. Analysts have adjusted their ratings and price targets in response to the company's performance and market dynamics.
The decrease in the average price target and mixed ratings indicate a cautious outlook from analysts, which could negatively impact investor sentiment and short-term stock performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100